HeartBeam Inc. (NASDAQ: BEAT) has announced the launch of a pilot study focused on evaluating its proprietary on-demand 12-lead ECG patch in detecting coronary artery disease and ischemia. The study marks a significant step in the development of the HeartBeam patch, which the company believes has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam's technology aims to address a critical gap in ambulatory monitoring.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could provide clinicians with valuable data to detect ischemia and other cardiac conditions earlier.”
The pilot study will evaluate the patch's ability to detect coronary artery disease and inadequate blood flow and oxygen supply to tissue, or ischemia. If successful, the HeartBeam patch could offer a non-invasive, convenient solution for long-term cardiac monitoring, potentially improving outcomes for patients with coronary artery disease.
HeartBeam's technology is designed to provide clinical-grade insights over extended periods, unlike existing patch-based monitors that lack ischemia detection capabilities. The company's focus on on-demand 12-lead ECG generation could differentiate it in the competitive cardiac monitoring landscape.
For more information, visit the company’s newsroom at https://nnw.fm/BEAT.
